GSA Capital Partners LLP Has $301,000 Stock Position in Personalis, Inc. $PSNL

GSA Capital Partners LLP reduced its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 62.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 46,193 shares of the company’s stock after selling 77,921 shares during the period. GSA Capital Partners LLP’s holdings in Personalis were worth $301,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Legal & General Group Plc acquired a new position in Personalis during the second quarter worth $30,000. Ameritas Investment Partners Inc. bought a new stake in Personalis during the 2nd quarter worth about $34,000. BNP Paribas Financial Markets boosted its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Personalis during the 3rd quarter worth about $66,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Personalis in the 2nd quarter valued at about $75,000. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on PSNL shares. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. HC Wainwright upped their price objective on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday. Guggenheim boosted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Morgan Stanley boosted their target price on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Personalis presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

Personalis Trading Up 0.3%

Shares of NASDAQ PSNL opened at $9.06 on Friday. The company has a market capitalization of $804.53 million, a P/E ratio of -9.96 and a beta of 1.98. Personalis, Inc. has a 12 month low of $2.83 and a 12 month high of $11.50. The stock has a 50 day moving average of $8.83 and a 200-day moving average of $7.96.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. Personalis had a negative return on equity of 42.81% and a negative net margin of 116.69%.The business had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis News Summary

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.